China's First Next-Generation Medical Heavy-Ion Therapy Accelerator Demonstration Facility Completed in Huizhou

Background

Heavy ion therapy is an advanced form of precision radiotherapy internationally recognized for treating certain tumors. Heavy ion beams, typically carbon ions, exhibit a unique depth-dose distribution known as the Bragg peak, where the majority of energy is deposited at a specific depth within tissue. This allows for highly conformal dose delivery to the tumor while minimizing exposure to surrounding healthy tissues. Additionally, heavy ions have higher relative biological effectiveness compared to conventional X-rays, making them particularly useful against tumors that are resistant to standard radiation or unsuitable for surgery.

What was achieved

The first demonstration facility of China's next-generation medical heavy-ion therapy accelerator, known as the ultra-compact rotating-beam heavy-ion therapy system or SIMM, has been completed at the Huizhou Heavy Ion Medical Center in Guangdong Province. The announcement was made on October 23, 2026, by the Institute of Modern Physics under the Chinese Academy of Sciences, which developed the system. This marks a milestone in the country's precision radiotherapy capabilities.

The SIMM system incorporates several technical innovations, including a new disc-type structure milliampere-level high-current linear injector, an ultra-short circumference high-rate synchrotron, and an internationally pioneering high-performance intelligent rotating beam delivery system. These reduce the device's footprint from 4,600 square meters in the first generation to 1,200 square meters, lower energy consumption to approximately one-third of previous levels, and increase annual treatment capacity from about 1,000 patients to 2,000-5,000 patients. Core technologies have received PCT patent authorizations in the United States, Europe, Japan, and South Korea, with one invention winning a gold award at the 26th China Patent Award. The unit has entered the equipment testing stage and is expected to begin clinical trials by the end of 2026.

China's heavy ion program began with research by the Institute of Modern Physics team in 1993. The first fully domestically developed heavy-ion accelerator for clinical treatment started operations in Wuwei, Gansu Province, in 2020, making China the fourth country after the United States, Germany, and Japan to achieve independent clinical application. Ten such domestically developed accelerators have been deployed nationwide. By the end of September 2026, nearly 5,000 patients had been treated, with reports of stable operation and notable clinical results.

How it works

In heavy ion therapy, particles such as carbon ions are accelerated to high speeds, often approaching a significant fraction of the speed of light, using a particle accelerator. The ions are then extracted and directed toward the patient through a beam transport line and a rotating delivery system that allows treatment from multiple angles. As the ions travel through tissue, they lose energy gradually at first but deposit the bulk of it abruptly near the end of their range in what is called the Bragg peak. Physicians use treatment planning software to position this peak precisely within the tumor volume, often employing intensity modulation and multi-field irradiation to match the dose to the tumor's three-dimensional shape.

The new SIMM demonstration facility employs a series of design changes for compactness and efficiency. These include the specialized high-current injector, a shortened synchrotron for faster acceleration cycles, and an intelligent rotating beam delivery system designed to optimize beam utilization. Sources indicate this configuration supports higher patient throughput by enabling more efficient scheduling and potentially allowing a single accelerator to interface with multiple treatment rooms. The system is intended for tumors where conventional radiotherapy may be less effective, with treatment typically involving a course of outpatient sessions planned according to the specific diagnosis and tumor characteristics.

What it means for international patients

The development and testing of this compact next-generation system in Huizhou could contribute to greater availability of heavy ion therapy capacity in China over time, as similar units are potentially deployed at additional sites. This may be relevant for international patients seeking advanced radiotherapy options for eligible tumor types, particularly given the system's reported improvements in efficiency and reduced facility requirements.

The Huizhou Heavy Ion Medical Center is located in Guangdong Province within the Greater Bay Area, which has growing international connectivity. However, the demonstration facility has not yet commenced clinical treatments and remains in the equipment testing phase ahead of planned trials by the end of 2026. No specific information on dedicated international patient services, language support, or VIP departments at this center was reported in official sources covering the announcement or the affiliated hospital.

International patients considering care at the Huizhou Heavy Ion Medical Center or similar facilities in China should contact the hospital directly to confirm eligibility for specific conditions, current operational status, treatment availability, required medical documentation, and any other practical arrangements. Suitability for heavy ion therapy must be determined by the treating physicians based on individual medical assessment.

About the hospital

The Huizhou Heavy Ion Medical Center is located in Huizhou, Guangdong Province, adjacent to the Jinshan campus of Huizhou Central People's Hospital, with which it shares resources via planned connections including an underground passage and dedicated wards. The center is a project of the public Huizhou Central People's Hospital, which received national approval in December 2025 from the National Health Commission as the first public hospital in South China to configure a heavy ion radiotherapy system.

Huizhou Central People's Hospital's tumor radiotherapy department was established in 1982 and is described as a leading facility in eastern Guangdong. It has introduced multiple precision radiotherapy technologies, including linear accelerators, brachytherapy equipment, and techniques such as stereotactic radiotherapy, AI-assisted 3D printing for brachytherapy, and active breathing control. The heavy ion project is positioned to address demand for advanced tumor treatment in the Greater Bay Area. The medical center itself is currently focused on commissioning the new demonstration accelerator developed in collaboration with the Institute of Modern Physics.